Opportunities and challenges of mRNA technologies in development of Dengue Virus Vaccine

Xiaoyang Liu, Daniel Salmon
{"title":"Opportunities and challenges of mRNA technologies in development of Dengue Virus Vaccine","authors":"Xiaoyang Liu, Daniel Salmon","doi":"arxiv-2409.10805","DOIUrl":null,"url":null,"abstract":"Dengue virus (DENV) is a mosquito-borne virus with a significant human health\nconcern. With 390 million infections annually and 96 million showing clinical\nsymptoms, severe dengue can lead to life-threatening conditions like dengue\nhemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved\nvaccine, Dengvaxia, has limitations due to antibody-dependent enhancement\n(ADE), necessitating careful administration. The recent pre-approval of TAK-003\nby WHO in 2024 highlights ongoing efforts to improve vaccine options. This\nreview explores recent advancements in dengue vaccine development, emphasizing\npotential utility of mRNA-based vaccines. By examining current clinical trial\ndata and innovations, we aim to identify promising strategies to address the\nlimitations of existing vaccines and enhance global dengue prevention efforts.","PeriodicalId":501219,"journal":{"name":"arXiv - QuanBio - Other Quantitative Biology","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"arXiv - QuanBio - Other Quantitative Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/arxiv-2409.10805","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Dengue virus (DENV) is a mosquito-borne virus with a significant human health concern. With 390 million infections annually and 96 million showing clinical symptoms, severe dengue can lead to life-threatening conditions like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement (ADE), necessitating careful administration. The recent pre-approval of TAK-003 by WHO in 2024 highlights ongoing efforts to improve vaccine options. This review explores recent advancements in dengue vaccine development, emphasizing potential utility of mRNA-based vaccines. By examining current clinical trial data and innovations, we aim to identify promising strategies to address the limitations of existing vaccines and enhance global dengue prevention efforts.
mRNA 技术在登革热病毒疫苗开发中的机遇与挑战
登革热病毒(DENV)是一种由蚊子传播的病毒,严重危害人类健康。每年有 3.9 亿人感染登革热,其中 9600 万人出现临床症状,严重的登革热可导致出血性登革热(DHF)和登革热休克综合征(DSS)等危及生命的病症。美国食品和药物管理局批准的唯一疫苗登革热疫苗(Dengvaxia)存在抗体依赖性增强(ADE)的局限性,需要谨慎用药。最近,世卫组织于 2024 年预先批准了 TAK-003 疫苗,这凸显了目前为改进疫苗选择所做的努力。本综述探讨了登革热疫苗研发的最新进展,强调了基于 mRNA 的疫苗的潜在效用。通过研究当前的临床试验数据和创新,我们旨在确定有前景的战略,以解决现有疫苗的局限性并加强全球登革热预防工作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信